BBIO BridgeBio Pharma

BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

PALO ALTO, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 11 AM (ET).



The presentation will be webcast live and can be accessed at  on the For Investors page under News & Events. The webcast will be available for replay through August 12, 2020.



About BridgeBio

BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.



Investor Contact:

John Grimaldi, Burns McClellan



212-213-0006 ext. 362



Media contact:

BridgeBio Pharma, Inc.

Grace Rauh



(917) 232-5478



Source: BridgeBio Pharma, Inc.

EN
06/05/2020

Underlying

BBIOBridgeBio Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BridgeBio Pharma

 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Reports Second Quarter 2025 Financial Results and Business U...

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates - As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment - $110.6 million in total second quarter revenue, comprised of $71.5 million of U.S. Attruby® net product revenue, $1.6 million from royalty revenue, and $37.5 million in license and services revenue - Attruby’s differentiated clinical profile was further strengthened by new analyses...

August 5, 2025 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence...

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 - By examining over 100 unique variants associated with the CASR gene causative of ADH1, the average frequency of gain-of-function CASR variants was ~3.7 per 100,000, closely aligned to previously published estimates1 (3.9 per 100,000), which equates to approximately 25,000 carriers of ADH1-causing variants in the US and EU - Only ~20% of individuals with genetic variants linked to ADH1 were found to have an es...

July 23, 2025 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio to Host Second Quarter 2025 Financial Results Conference Cal...

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webc...

July 22, 2025 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Raises $300 Million Through Partial Capped Monetization of B...

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty BridgeBio has received a $300 million upfront payment, strengthening the Company’s balance sheet, and supporting the launch of Attruby® and ongoing late-stage pipeline programsTransaction monetizes 60% of BridgeBio’s European royalties on the first $500 million of annual BEYONTTRA net sales, with total payments to the investors subject to an initial cap of 1.45xIn the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM ...

June 30, 2025 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor W...

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio. Dr. Wicklund wi...

June 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch